NZ210816A - Dihydropyridazinones and pharmaceutical compositions - Google Patents

Dihydropyridazinones and pharmaceutical compositions

Info

Publication number
NZ210816A
NZ210816A NZ210816A NZ21081685A NZ210816A NZ 210816 A NZ210816 A NZ 210816A NZ 210816 A NZ210816 A NZ 210816A NZ 21081685 A NZ21081685 A NZ 21081685A NZ 210816 A NZ210816 A NZ 210816A
Authority
NZ
New Zealand
Prior art keywords
compound
formula
methyl
pyridazinone
dihydro
Prior art date
Application number
NZ210816A
Other languages
English (en)
Inventor
R A Slater
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of NZ210816A publication Critical patent/NZ210816A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
NZ210816A 1984-01-13 1985-01-11 Dihydropyridazinones and pharmaceutical compositions NZ210816A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (1)

Publication Number Publication Date
NZ210816A true NZ210816A (en) 1987-06-30

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ210816A NZ210816A (en) 1984-01-13 1985-01-11 Dihydropyridazinones and pharmaceutical compositions

Country Status (31)

Country Link
US (1) US4654342A (OSRAM)
EP (1) EP0150937B1 (OSRAM)
JP (3) JPS60158181A (OSRAM)
KR (1) KR920006781B1 (OSRAM)
CN (1) CN85101722A (OSRAM)
AT (1) ATE37179T1 (OSRAM)
AU (1) AU572252B2 (OSRAM)
CA (2) CA1251209A (OSRAM)
CS (1) CS248731B2 (OSRAM)
DD (1) DD231350A5 (OSRAM)
DE (1) DE3564941D1 (OSRAM)
DK (1) DK162519C (OSRAM)
ES (3) ES8607949A1 (OSRAM)
FI (1) FI850140A7 (OSRAM)
GB (1) GB8400863D0 (OSRAM)
GR (1) GR850068B (OSRAM)
HU (1) HU193591B (OSRAM)
IE (1) IE57969B1 (OSRAM)
IL (1) IL74031A (OSRAM)
JO (1) JO1351B1 (OSRAM)
MY (1) MY100124A (OSRAM)
NO (1) NO850129L (OSRAM)
NZ (1) NZ210816A (OSRAM)
PH (1) PH22136A (OSRAM)
PL (1) PL147123B1 (OSRAM)
PT (1) PT79819B (OSRAM)
RO (1) RO92607A (OSRAM)
SU (1) SU1396963A3 (OSRAM)
WO (1) WO1985003076A1 (OSRAM)
ZA (1) ZA85251B (OSRAM)
ZW (1) ZW385A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
EP1377282B1 (en) * 2001-02-27 2006-08-16 MIGENIX Corp. Aryl-n-cyanoguanidines and methods related thereto
CN1585641A (zh) * 2001-11-05 2005-02-23 默克专利有限公司 亚肼基-丙二腈化合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
JP5312034B2 (ja) * 2005-11-14 2013-10-09 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 無症候性(潜在性)心不全の治療のためのpdeiii阻害剤の使用
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL2370070T3 (pl) 2008-11-25 2014-02-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN107090016A (zh) 2011-03-01 2017-08-25 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
DK3021832T3 (da) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
ES2593210T3 (es) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
EP0030835B1 (en) * 1979-12-05 1983-05-11 Morishita Pharmaceutical Co. Ltd. Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
DE3263497D1 (en) * 1981-03-04 1985-06-20 Ciba Geigy Ag Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants

Also Published As

Publication number Publication date
CA1260471A (en) 1989-09-26
AU572252B2 (en) 1988-05-05
ES539446A0 (es) 1986-06-01
EP0150937B1 (en) 1988-09-14
DK162519B (da) 1991-11-11
SU1396963A3 (ru) 1988-05-15
WO1985003076A1 (en) 1985-07-18
DK162519C (da) 1992-03-30
PH22136A (en) 1988-06-01
FI850140L (fi) 1985-07-14
IL74031A (en) 1988-07-31
ES8703846A1 (es) 1987-03-01
IL74031A0 (en) 1985-04-30
HU193591B (en) 1987-11-30
DD231350A5 (de) 1985-12-24
ES549629A0 (es) 1987-03-01
GR850068B (OSRAM) 1985-05-03
CN85101722A (zh) 1987-01-31
PL147123B1 (en) 1989-04-29
US4654342A (en) 1987-03-31
KR920006781B1 (ko) 1992-08-17
ES8607949A1 (es) 1986-06-01
HUT37128A (en) 1985-11-28
JO1351B1 (en) 1986-11-30
ZW385A1 (en) 1985-08-07
NO850129L (no) 1985-07-15
ZA85251B (en) 1986-08-27
PL251516A1 (en) 1985-12-17
JPS63313775A (ja) 1988-12-21
PT79819B (en) 1987-01-07
JPS60158181A (ja) 1985-08-19
CS248731B2 (en) 1987-02-12
KR850005417A (ko) 1985-08-26
DE3564941D1 (en) 1988-10-20
ATE37179T1 (de) 1988-09-15
AU3761185A (en) 1985-07-18
EP0150937A2 (en) 1985-08-07
MY100124A (en) 1989-12-18
PT79819A (en) 1985-02-01
IE57969B1 (en) 1993-06-02
RO92607A (ro) 1987-11-30
DK9185D0 (da) 1985-01-08
CA1251209A (en) 1989-03-14
IE850069L (en) 1985-07-13
CA1260471C (OSRAM) 1989-09-26
FI850140A7 (fi) 1985-07-14
FI850140A0 (fi) 1985-01-11
DK9185A (da) 1985-07-14
GB8400863D0 (en) 1984-02-15
EP0150937A3 (en) 1985-08-21
ES554965A0 (es) 1987-07-01
JPS63313776A (ja) 1988-12-21
ES8706645A1 (es) 1987-07-01

Similar Documents

Publication Publication Date Title
NZ210816A (en) Dihydropyridazinones and pharmaceutical compositions
US5075310A (en) Pyrimidone derivatives as bronchodilators
EP0371731B1 (en) Quinazolinone derivatives
US3995039A (en) Pyrazolo [1,5-a] [1,3,5] triazines
EP0208518B1 (en) 6-phenyl-pyridazinyl compounds
EP0201988B1 (en) Dihydropyridazinone derivatives
US4766123A (en) Methylamidine compounds
EP0199465B1 (en) Cyanoalkanimidamido compounds
SU1342416A3 (ru) Способ получени производных пиридазинона или их водорастворимых солей с фармацевтически приемлемой кислотой
EP0134096B1 (en) Aminopyrimidinone derivatives as histamine h2-antagonists
EP0107914A1 (en) Aminopyrimidinone derivatives useful as histamine H1-antagonists
US4962110A (en) Pyridazinone derivatives
US4683228A (en) Guanidinopyrazolylamides, guanidimoimidazolylamides, compositions containing them, and method of using them to inhibit gastric acid secretion
KR890002425B1 (ko) 1-(하이드록시페닐)-3-메틸-4-디플루오로메틸-△²-1,2,4-트리아졸린-5-온 유도체의 제조방법
JP2757353B2 (ja) インダン誘導体、その製法及びその合成中間体
EP0197664A2 (en) 2-Aminopyrimidinone derivatives
AT367049B (de) Verfahren zur herstellung von neuen pyrimidonderivaten
EP0193660A1 (en) 1-(Hydroxyphenyl)-3-methyl-4-difluoromethyl-(delta-2)-1,2,4-triazolin-5-one derivatives
EP0103390A2 (en) Guanidine-containing esters as histamine H2 receptor blockers
JPS6212764A (ja) ジヒドロピリダジノン誘導体
CS241535B2 (cs) Způsob výroby derivátů guanidinu